6024 POSTER Treatment outcome in patients with advanced-stage Hodgkin's lymphoma after developing drug intolerance to components of ABVD or BEACOPP regimens

T.Bogatyreva; T.Kravtchenko; E.Strelnikova; T.Nestaiko

首页> 外文期刊>European Journal of Cancer Supplements >6024 POSTER Treatment outcome in patients with advanced-stage Hodgkin's lymphoma after developing drug intolerance to components of ABVD or BEACOPP regimens

【24h】

6024 POSTER Treatment outcome in patients with advanced-stage Hodgkin's lymphoma after developing drug intolerance to components of ABVD or BEACOPP regimens

机译：对ABVD或BEACOPP方案的药物不耐受的晚期霍奇金淋巴瘤患者的6024 POSTER治疗结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
T.Bogatyreva; T.Kravtchenko; E.Strelnikova; T.Nestaiko;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. [J] . Diehl V, Franklin J, Hasenclever D, Journal of Clinical Oncology . 1998,第12期

机译：BEACOPP，一种新的剂量递增和加速方案，在晚期霍奇金淋巴瘤患者中至少与COPP / ABVD一样有效：德国霍奇金淋巴瘤研究小组的一项试验的中期报告。
2. ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis [J] . Vijenthira Abi, Cheung Matthew C., Phua Chai Wye, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：ABVD与联合基线Beacopp /升高的Beacopp治疗新诊断的晚期霍奇金淋巴瘤：决策分析
3. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan [J] . Kedmi Meirav, Apel Arie, Davidson Tima, Acta Haematologica . 2016,第3期

机译：高危，晚期霍奇金淋巴瘤：中期FDG-PET / CT扫描迅速升级代谢完全缓解患者联合BEACOPP和ABVD治疗的影响
4. Developing New Dry Powder Drug Delivery Products with Improved Patient Outcomes [C] . Mark A. Tracy Annual meeting exposition of the Controlled Release Society . 2005

机译：开发新的干粉药物输送产品，改善患者结果
5. Clinical outcomes and cost-effectiveness of white blood cell growth factors in elderly patients with non -Hodgkin's lymphoma: Findings from a large population-based cohort. [D] . Gruschkus, Stephen K. 2009

机译：非霍奇金淋巴瘤的老年患者的白细胞生长因子的临床结果和成本效益：基于大量人群的研究结果。
6. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP [O] . Ron Daniel Jachimowicz, Luise Pieper, Sarah Reinke, 2021

机译：肿瘤微环境的全载图像分析将低B细胞含量鉴定为患有Beacopp治疗的晚期常规霍奇金淋巴瘤患者不良结果的预测因子
7. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses [O] . Gallamini, A, Patti, C, Viviani, S, 2011

机译：在两次ABVD疗程过后中期PET呈阳性的晚期霍奇金淋巴瘤患者中，使用BEACOPP进行早期化学强化治疗

6024 POSTER Treatment outcome in patients with advanced-stage Hodgkin's lymphoma after developing drug intolerance to components of ABVD or BEACOPP regimens

著录项

相似文献

相关主题

期刊订阅